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Abstract There is no consensus on the role of insulin secreted
from pancreatic L-cells in regulating its own secretion, either in
rodent islets or in human islets. We have now investigated
whether there is an autocrine signalling role for insulin in human
islets by determining insulin receptor expression and assessing
the effects of insulin receptor activation using a non-peptidyl
insulin mimetic termed L-783,281. Human insulin receptor
mRNA was detected by PCR amplification of human islet
cDNA, and translation of the message in human islets was
confirmed by Western blotting. Perifusion experiments revealed
that both glucose-stimulated and basal insulin secretion were
significantly inhibited following human islet insulin receptor
activation with L-783,281, and that signalling through phospha-
tidylinositol 3-kinase (PI 3-kinase) was responsible, at least in
part, for this inhibitory effect. These studies indicate that human
islets express insulin receptors and that they are functionally
coupled to a PI 3-kinase-dependent inhibition of insulin
secretion. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The regulated release of insulin from pancreatic L-cells is
pivotal for the maintenance of serum glucose concentrations
within the physiological range. Glucose itself is the major
physiological stimulus for insulin secretion, but a number of
hormones and neurotransmitters can act at L-cells to modu-
late the secretory process [1]. It has long been known that
glucagon released from pancreatic K-cells potentiates glu-
cose-stimulated insulin secretion [2], while the N-cell hormone
somatostatin inhibits insulin secretion [3]. However, there is
considerable uncertainty about the autocrine e¡ects of insulin
on insulin secretion from L-cells. In other cell types it is well-
established that insulin binds to the heterotetrameric insulin
receptor, stimulating its intrinsic tyrosine kinase activity, lead-
ing to autophosphorylation of the receptor L subunits and
tyrosine phosphorylation of intracellular proteins known as
insulin receptor substrates (IRS). The phosphorylated IRS
proteins act as docking proteins for SH2-containing e¡ector
proteins that mediate the signalling events initiated by insulin
[4].
Radioligand binding studies have suggested that puri¢ed
islet L-cells do not express high a⁄nity insulin receptors [5],
while more recent studies using single cell polymerase chain
reaction (PCR) have indicated that rat L-cells co-express in-
sulin, insulin receptor and IRS-1 mRNAs [6]. The lack of
consensus in this area extends to the e¡ects of insulin on
insulin secretion. There have been reports that insulin does
not a¡ect insulin secretion [7^9], that it inhibits [10^13], or
that it stimulates [14^16] insulin secretion. Some of the con-
fusion arising from these studies may have resulted from the
measurement of insulin levels by radioimmunoassay following
exposure to insulin in vitro, making it di⁄cult to distinguish
between secretion of endogenous hormone and the contribu-
tion made by the exogenous insulin. Further discrepancies in
the literature may also be caused by comparing in vivo studies
in humans with in vitro experiments primarily using islets or
L-cell lines derived from rodents. Other potentially confound-
ing factors include the use of non-physiological concentrations
of insulin; measurement of insulin release in static incubations
where potentially inhibitory products could accumulate; in
vivo studies where the responses do not necessarily re£ect
direct e¡ects of insulin on the islets; and indirect estimates
of L-cell secretory activity using microelectrodes. Despite the
lack of consensus regarding the e¡ects of insulin on the exo-
cytotic release of insulin from L-cells, studies using rodent
islets and HIT-T15 cells have provided very good evidence
that insulin stimulates insulin gene transcription through
phosphatidylinositol 3-kinase (PI 3-kinase) Ia/p70 S6 kinase
and CaM kinase pathways [17,18], and that it regulates glu-
cokinase gene transcription through PI 3-kinase II/protein ki-
nase B pathways [18]. The capacity of insulin to exert biolog-
ical e¡ects on gene transcription in islets and a L-cell line
strongly supports the presence of insulin receptors and down-
stream signalling elements by L-cells.
Many of the experimental di⁄culties associated with iden-
tifying the e¡ect of insulin on insulin secretion can be circum-
vented by selectively activating insulin receptors with an in-
sulin-mimetic which is without insulin immunoreactivity. A
non-peptidyl fungal metabolite, termed L-783,281, has been
shown to mimic many of insulin’s e¡ects in vitro and in
vivo through activation of the insulin receptor L subunit ty-
rosine kinase activity [19], and this agent has been reported to
stimulate insulin gene expression in mouse L-cells [16]. We
have now used L-783,281 to establish the consequences of
short-term activation of insulin receptors on dynamic insulin
secretion from human islets of Langerhans.
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2. Materials and methods
2.1. Human islet isolation
Human islets were provided by Dr Guo Cai Huang of the Dixon’s
Human Islet Project (King’s College Hospital, London, UK). Brie£y,
pancreata were retrieved, with permission, from non-diabetic heart-
beating cadaver organ donors, and islets were isolated under aseptic
conditions according to the method of London and colleagues [20].
Islets were used after maintenance overnight in CMRL medium sup-
plemented with 15% foetal calf serum, 100 U/ml penicillin and 100 Wg/
ml streptomycin. All tissue culture reagents were obtained from Gibco
(Paisley, UK). Electron micrographs indicated that hand-picked hu-
man islets were s 90% pure.
2.2. PCR
Messenger RNA was isolated from hand-picked human islets using
a Dynabeads Oligo(dT)25 kit according to the manufacturer’s instruc-
tions (Dynal, Merseyside, UK). Oligo(dT)18 (1 Wg) and random 10-
mers (1 Wg) were added to islet mRNA (10 Wl) and the mixture was
heated (70‡C, 5 min) to remove secondary RNA structure, then
cooled on ice. Dithiothreitol (10 mM), dATP, dCTP, dTTP and
dGTP (all 0.5 mM), recombinant ribonuclease inhibitor (80 U, RNa-
sin), MMLV-RT (200 U) and molecular biology grade water were
added to give a ¢nal volume of 20 Wl, and the mixture was incubated
at 42‡C for 50 min. MMLV-RT was inactivated by heating at 70‡C
for 15 min. The cDNA was ampli¢ed by 30 cycles of PCR using
primers that detected human insulin receptor (forward: 5P-CAG
CGA GAA ACT GCA TGG T-3P ; reverse: 5P-CAT TGG ACA
TGG TAG AGT CG-3P). The predicted size of the human insulin
receptor PCR product was 770 bp. PCR reactions were also per-
formed using MIN6 L-cells and mouse liver, using primers that de-
tected the mouse insulin receptor (forward: 5P-ATC TGG ATC CCC
CTG ATA ACT GTC-3P ; reverse: 5P-ATG TGG GTG TAG GGG
ATG TGT TCA-3P). The predicted size of the mouse insulin receptor
product was 331 bp. PCR products ampli¢ed by the insulin receptor
primers were separated by agarose gel electrophoresis (2% w/v) and
visualised by staining with ethidium bromide (0.5 Wg/ml). The PCR
products were excised from the gels and their identities were con-
¢rmed by sequencing using standard £uorescent chain-terminator
methods.
2.3. Western blot analysis
Human islets were hand-picked from the islet digest provided by Dr
Huang, using a ¢nely drawn capillary glass pipette and transferred to
polyacrylamide gel electrophoresis sample bu¡er [21]. Human islet
proteins were fractionated by electrophoresis on 10% polyacrylamide
Bis-Tris gels (Invitrogen, Groningen, The Netherlands) and trans-
ferred to polyvinylidene £uoride membranes using the Novex Xcell
II blotting apparatus (Invitrogen). Insulin receptor expression was
identi¢ed by immunoprobing membranes with a rabbit polyclonal
antibody raised against the insulin receptor K subunit (Autogen Bio-
clear, Wiltshire, UK) and a horseradish peroxidase-linked goat anti-
rabbit secondary antibody (Pierce, Rockford, IL, USA). Immunore-
active proteins were detected by ECL1 (Amersham International plc,
Bucks, UK).
2.4. Insulin secretion
Human islets were transferred to Swinnex chambers (Millipore,
Bedford, MA, USA) containing 1 Wm pore-size nylon ¢lters and peri-
fused at a £ow rate of 0.5 ml/min at 37‡C in a temperature-controlled
environment. Islets were initially perifused with a physiological bu¡er
[22] containing 2 mM glucose for 1 h and insulin secreted from the
islets into the perifusate during this period was discarded. Islets were
then perifused with bu¡ers containing 2 or 20 mM glucose, either in
the absence or in the presence of 10 WM L-783,281 (Merck Research
Laboratories, Rahway, NJ, USA). L-783,281 was stored as a 20 mM
stock in dimethyl sulfoxide (DMSO) at 320‡C. For use in experi-
ments it was initially diluted to 5 mM in DMSO, then further diluted
to 10 WM in protein-free aqueous bu¡er. In some experiments bu¡ers
were supplemented with 20 WM LY 294002 (Calbiochem, Notting-
ham, UK), a PI 3-kinase inhibitor. Perifusate fractions were collected
every 2 min and insulin content was determined by radioimmunoassay
[21]. The e¡ects of DMSO alone were examined in static incubations
where groups of three hand-picked human islets were incubated for 30
min at 37‡C at 2 mM or 20 mM glucose in the absence or presence of
0.2% (v/v) DMSO, and insulin content of the supernatant was as-
sessed by radioimmunoassay.
3. Results
3.1. Human islets express insulin receptor mRNA
Fig. 1 shows images of ethidium bromide-stained agarose
gels in which insulin receptor cDNA had been ampli¢ed from
hand-picked human islets (left) and mouse liver and MIN6
cells (right). Products of the appropriate sizes were obtained
and their identities were con¢rmed by sequencing using £uo-
rescent chain-terminator methods.
3.2. Human islet insulin receptor mRNA is translated into
protein
Translation of insulin receptor mRNA into protein was
con¢rmed by Western blotting using an antibody raised
against the extracellular K subunit of the insulin receptor. It
can be seen from Fig. 2 that both human islets and mouse
skeletal muscle contained a 130 kDa immunoreactive protein,
consistent with the molecular mass of the insulin receptor K
subunit and indicative of the presence of the insulin receptor
complex in human islet cells as well as in mouse skeletal
muscle.
3.3. Activation of human islet insulin receptors inhibits
insulin secretion
Perifusion experiments with human islets isolated from two
separate donors indicated that insulin secretion was signi¢-
cantly stimulated upon raising the glucose concentration
from 2 mM to 20 mM, as expected (Fig. 3, upper panel).
Addition of the insulin mimetic, L-783,281, at 10 WM resulted
in a signi¢cant (P6 0.05) inhibition of glucose-induced insulin
secretion, such that the secretory response approached basal
levels of insulin secretion (Fig. 3, upper panel). The e¡ects of
activation of human islet insulin receptors with L-783,281 at
2 mM glucose were also examined. It can be seen from Fig. 3
(lower panel) that 10 WM L-783,281 elicited a rapid inhibition
of basal insulin secretion that was partially reversible when
the perifusion medium was returned to 2 mM glucose alone.
The inhibitory e¡ects of L-783,281 were mediated, at least in
part, through a PI 3-kinase-sensitive pathway, since they were
reduced in the presence of the PI 3-kinase inhibitor LY
294002 (2 mM glucose+10 WM L-783,281: 53 þ 2.0% basal
Fig. 1. Ampli¢cation of insulin receptor cDNA in human islets
(lane 1), mouse liver (lane 2) and MIN6 L-cells (lane 3). PCR prod-
ucts were separated on 2% agarose gels. No products were obtained
when water rather than cDNA was included in the PCR reactions.
Fig. 2. Insulin receptor K subunit immunoreactivity in mouse skele-
tal muscle (lanes 1^3) and hand-picked human islets (lanes 4^7). 20,
10 and 5 Wg protein was loaded on to lanes 1^3, and protein from
40, 20, 10 and ¢ve hand-picked human islets was loaded on to lanes
4^7.
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secretion; +20 WM LY 294002: 107 þ 9.4% basal, n = 3,
P6 0.01). However, the capacity of 20 WM LY 294002 alone
to stimulate secretion at 2 mM glucose (144 þ 9.8% basal se-
cretion) makes it di⁄cult to fully de¢ne the role of PI 3-kinase
in the inhibition of secretion by L783,281.
Inhibition of insulin secretion by L783,281 could not be
attributed to vehicle since 0.2% DMSO did not have any sig-
ni¢cant e¡ect on basal nor glucose-stimulated insulin secre-
tion (2 mM glucose: 0.35 þ 0.02 ng/islet/30 min; 2 mM glu-
cose+DMSO: 0.34 þ 0.02; 20 mM glucose: 1.03 þ 0.06; 20
mM glucose+DMSO: 1.08 þ 0.08; n = 7^8; P6 0.0001, 2 mM
vs 20 mM glucose; Ps 0.2 for the e¡ect of DMSO).
4. Discussion
There is very little information available about the regula-
tion of insulin secretion from human islets as a result of the
scarcity of human islet tissue available for experimentation,
and to date there are no publications on the expression and
e¡ects of activation of human islet insulin receptors in vitro.
The current study has shown that isolated human islets
express mRNA for the human insulin receptor and that this
message is translated into protein since the 130 kDa insulin
receptor K subunit was also detected by Western blotting. It is
not clear from our experiments which islet cell type expresses
the insulin receptor, but given that human islets contain at
least 50% L-cells [23] and that isolated K-cells do not bind
insulin [24], it seems likely that some, if not all, of the insulin
receptor immunoreactivity on human islets can be attributed
to L-cells. In addition, since insulin receptor mRNA could be
detected in a mouse L-cell line (MIN6) by PCR, it seems likely
that insulin receptors are also expressed on human L-cells.
The insulin receptors on human islets are functionally
coupled to insulin secretion, as evidenced by the e¡ect of L-
783,281, an insulin mimetic, on insulin secretion from peri-
fused human islets. Our data support a role for insulin pro-
voking a negative feedback e¡ect on L-cells to inhibit both
sustained glucose-stimulated insulin secretion and unstimulat-
ed insulin secretion. Thus, the inhibition of glucose-induced
insulin release evoked by L-783,281 is consistent with several
earlier studies [10^13], but directly contradicts others [14,15].
The reasons for the lack of concordance between the results of
the present study and those of Aspinwall and colleagues
[14,15] are not clear, but may re£ect species di¡erences (hu-
man versus mouse islets) or di¡erences in the method used to
measure insulin secretion (radioimmunoassay versus amper-
ometry). The inhibition of secretion seen in the current study
is consistent with the recent observation that insulin hyper-
polarises mouse L-cells through activation of ATP-sensitive
K channels [25].
Our observation that activation of islet insulin receptors
resulted in a profound inhibition of basal insulin secretion
was somewhat unusual as modulators of L-cell function rarely
inhibit unstimulated insulin release. However, the inhibitory
pro¢le at 2 mM glucose obtained in response to L-783,281 in
the current studies is reminiscent of that seen in response to
elevated extracellular Ca2 levels in human islets [26], and it is
clear that insulin secretion obtained in the absence of stimu-
latory concentrations of glucose is a regulated process, rather
than just leakage. The inhibitory e¡ect of L-783,281 on basal
secretion was also surprising since insulin might be expected
to inhibit insulin secretion by a negative feedback route only
after its secretion in response to L-cell stimulation. However,
the current data are indicative of a role for insulin released
from unstimulated L-cells in maintaining the L-cells in a basal
state, potentially preventing dysregulated insulin secretory
output and fully support the proposal of Khan and colleagues
that insulin has a physiological autocrine role as a negative
feedback signal in L-cells [25]. These observations are also
consistent with those of a previous study in which selective
inactivation of the L-cell insulin receptor gene in mice was
associated with signi¢cant increases in their fasting insulin
levels [27].
Previous studies using PI 3-kinase inhibitors have demon-
strated the involvement of this enzyme in transducing insulin-
mediated signalling in rodent L-cells [17,18,25,28], and it has
been reported that PI 3-kinase is active in L-cells under non-
stimulatory conditions [29]. The reduced inhibitory capacity
of L-783,281 in the presence of LY 294002, a PI 3-kinase
inhibitor, suggests a key role for PI 3-kinase in transducing
the L-783,281-mediated inhibition of insulin secretion from
human islets. The raised basal secretion in the presence of
LY 294002 is also consistent with a tonic inhibition of insulin
secretion through a PI 3-kinase-sensitive pathway, and con-
¢rms previously published data in the MIN6 insulin-secreting
cell line [30].
In conclusion, this study has shown that human islets, like
Fig. 3. Inhibition of glucose-stimulated (upper panel) and basal
(lower panel) insulin secretion from perifused human islets by L-
783,281. Data show means þ S.E.M. of eight separate perifusion
chambers using islets isolated from two donors. Where error bars
are not shown they are smaller than the size of the symbol.
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rodent islets and L-cell lines, express functionally active insulin
receptors and that insulin secreted from human pancreatic L-
cells acts in an autocrine manner at insulin receptors to neg-
atively regulate its own secretion. Such a negative feedback
mechanism may play a role in the biphasic pro¢le of insulin
secretion, as has been proposed by other investigators [11],
but our study suggests that it is also important in regulating
the basal insulin secretory activity of L-cells. Our demonstra-
tion of autocrine regulation of L-cell function in primary hu-
man islets raises the intriguing possibility that defects in this
regulatory system are involved in the development of pathol-
ogies associated with dysfunctional insulin secretion, such as
Type 2 diabetes [31] or persistent hyperinsulinaemic hypogly-
caemia of infancy [32].
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